tbuckley/cabot-search huggingface dataset:
Dysregulation of angiopoietin-1 plays a mechanistic role in the pathogenesis of cerebral malaria
Authors: Sarah J. Higgins, Lisa A. Purcell, Karlee L. Silver, Vanessa Tran, Valerie Crowley, Michael Hawkes, Andrea L. Conroy, Robert O. Opoka, John G. Hay, Susan E. Quaggin, Gavin Thurston, W. Conrad Liles, Kevin C. Kain
Journal: Science Translational Medicine (2016)

Cerebral malaria is a leading cause of global morbidity and mortality. Interventions targeting the underlying pathophysiology of cerebral malaria may improve outcomes compared to treatment with antimalarials alone. Microvascular leak plays an important role in the pathogenesis of cerebral malaria. The angiopoietin (Ang)-Tie-2 system is a critical regulator of vascular function. We show that Ang-1 expression and soluble Tie-2 expression were associated with disease severity and outcome in a prospective study of Ugandan children with severe malaria and in a preclinical murine model of experimental cerebral malaria. Ang-1 was necessary for maintenance of vascular integrity and survival in a mouse model of cerebral malaria. Therapeutic administration of Ang-1 preserved blood-brain barrier integrity and, in combination with artesunate treatment, improved survival beyond that with artesunate alone. These data define a role for dysregulation of the Ang-Tie-2 axis in the pathogenesis of cerebral malaria and support the evaluation of Ang-Tie-2-based interventions as potential adjunctive therapies for treating severe malaria.
Radical Treatment of Non-Small Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (NCT01282450)
Authors: D. De Ruysscher, R. Wanders, A. van Baardwijk, A.C. Dingemans, B. Reymen, G. Bootsma, C. Pitz, W. Geraedts, B. Baumert, P. Lambin
Journal: Annals of Oncology (2012)
Mechanism of Resistance to Azacitidine in Myelodisplastic Syndromes.
Authors: Ana Belen Valencia Martinez, Alessandro Martino, Francesca Buchi, Erico Masala, Alessandro Sanna, Federico Canzian, Daniela Cilloni, Valentina Gaidano, Antonella Gozzini, Alberto Bosi, Valeria Santini
Journal: Blood (2012)
346PD Evaluation of safety, tolerability, pharmacokinetics (PK) and efficacy of dabrafenib and trametinib combination (Dab + Tra) therapy in Japanese patients (pts) with BRAF V600 mutation-positive advanced cutaneous melanoma: a phase (Ph) I/II study
Authors: A. Tsutsumida, N. Yamazaki, A. Takahashi, K. Namikawa, Y. Fujiwara, S. Kondo, S. Yoshikawa, Y. Yoshino, A. Suzuki, A. Mukaiyama, Y. Nishimura, Y. Kiyohara
Journal: Annals of Oncology (2015)
Pediatric low-grade gliomas: implications of the biologic era
Authors: Roger J. Packer, Stephan Pfister, Eric Bouffet, Robert Avery, Pratiti Bandopadhayay, Miriam Bornhorst, Daniel C. Bowers, David Ellison, Jason Fangusaro, Nicholas Foreman, Maryam Fouladi, Amar Gajjar, Daphne Haas-Kogan, Cynthia Hawkins, Cheng-Ying Ho, Eugene Hwang, Nada Jabado, Lindsay B. Kilburn, Alvaro Lassaletta, Keith L. Ligon, Maura Massimino, Schouten-van Meeteren, Sabine Mueller, Theo Nicolaides, Giorgio Perilongo, Uri Tabori, Gilbert Vezina, Katherine Warren, Olaf Witt, Yuan Zhu, David T. Jones, Mark Kieran
Journal: Neuro-Oncology (2016)

For the past decade, it has been recognized that pediatric low-grade gliomas (LGGs) and glial-neuronal tumors carry distinct molecular alterations with resultant aberrant intracellular signaling in the Ras–mitogen-activated protein kinase pathway. The conclusions and recommendations of a consensus conference of how best to integrate the growing body of molecular genetic information into tumor classifications and, more importantly, for future treatment of pediatric LGGs are summarized here. There is uniform agreement that molecular characterization must be incorporated into classification and is increasingly critical for appropriate management. Molecular-targeted therapies should be integrated expeditiously, but also carefully into the management of these tumors and success measured not only by radiographic responses or stability, but also by functional outcomes. These trials need to be carried out with the caveat that the long-term impact of molecularly targeted therapy on the developing nervous system, especially with long duration treatment, is essentially unknown.
Human multipotent adult progenitor cells (MAPC) can differentiate in vitro and vivo into arterial and venous endothelium
Authors: Xabier Lopez Aranguren, C Clavel, Aernout Luttun, MA Barajas, C Moreno, G Abizanda, A Echavarri, M Arana, M Soriano, EJ Andreu, JM Garcia-Verdugo, Catherine Verfaillie, F Prosper
Journal: Circulation (2005)
Pre-Engraftment Serum C-Reactive Protein (CRP) Value as a Predictor of Acute Graft-Versus-Host Disease and Non-Relapse Mortality.
Authors: Shigeo Fuji, Sung-Won Kim, Takahiro Fukuda, Shin-ichiro Mori, Satoshi Yamasaki, Yuriko Morita-Hoshi, Fusako Ohara-Waki, Yuji Heike, Kensei Tobinai, Ryuji Tanosaki, Yoichi Takaue
Journal: Blood (2007)
P0881 : Real world effectiveness and cost of simeprevir- and/or sofosbuvir-based HCV treatments: $175,000 per SVR12
Authors: K. Bichoupan, N. Tandon, D. Del Bello, N. Patel, R. Yalamanchili, S. Chekuri, A. Harty, S. Chang, L. Ku, M. Ng, D.B. Motamed, K.M. Sigel, D. Gardenier, A. Stivala, V. Khaitova, M.B. Bansal, P. Grewal, R. Agarwal, C.Y. Chang, J. Leong, G.Y. Im, L.U. Liu, J.A. Odin, N. Bach, S.L. Friedman, T.D. Schiano, P. Perumalswami, D.T. Dieterich, A.D. Branch
Journal: Journal of Hepatology (2015)
Prognostic factors in metastatic renal cell carcinoma after failure of immunotherapy: Lessons from a large phase III trial
Authors: B. Escudier, P. Venner, L. Stern, M. Donovan, D. Croteau, P. Champagne, R. Bukowski
Journal: Journal of Clinical Oncology (2004)

4547 Background: Immunotherapy (IT) remains first-line treatment for metastatic renal cell carcinoma (RCC). For patients (pts) with progressive disease following IT, no treatment is available, and new approaches are needed. However, prognostic factors (PF) in this patient population are not yet well described. We reported the results of a prospective, randomized, double-blind, placebo-controlled trial of Neovastat in pts who failed IT (Escudier et al, ECCO 2003). Neovastat failed to improve survival in this group of pts. Data from that trial were analyzed to evaluate the effect of PF on survival for pts failing IT. Methods: using univariate (UVA) and multivariate (MVA) analyses, 300 pts were evaluated for recognized PF in RCC pts: ECOG PS, nephrectomy, time from diagnosis to metastasis (TDM), number and site of metastases, and biological variables previously defined by Motzer (same cut-off values): hemoglobin (Hb), corrected calcium (CAc), albumin, LDH, alkaline phosphatase (AP). Results: the overall survival was 12.6 months. In UVA, differences were observed for : ECOG PS (p<0.001), number of metastatic sites (p= 0.002), bone mets (p=0.02), prior radiotherapy (p=0.001), TDM (p<0.001), Hb (p=0.0004), albumin (p=0.002), CAc and AP (p<0.001), but no difference was observed for lung or liver mets, or LDH (p=0.018). In MVA, TDM, metastatic sites, AP and CAc remained significant. When categorizing pts by Motzer risk factors, overall survival differed between the 4 risk groups (p<0.001). Median survival was similar with 0 or one risk factor (447 days), and was shorter in pts with 2 risk factors (301 days) or 3+ risk factors (121 days) Conclusions: median survival of metastatic RCC pts who failed first-line treatment (and are eligible for 2nd line treatment) is 12.6 months. PF are similar to those described in first-line, except for LDH. Motzer PF groups apply in this post IT population. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aeterna Laboratories Aeterna Roche
Functionalised carbon nanotubes: From intracellular uptake and cell-related toxicity to systemic brain delivery
Authors: Pedro M. Costa, Maxime Bourgognon, Julie T-W Wang, Khuloud T. Al-Jamal
Journal: Journal of Controlled Release (2016)

Carbon nanotubes (CNTs) have long been regarded as promising carriers in biomedicine. Due to their high surface area and unique needle-like structure, CNTs are uniquely equipped to carry therapeutic molecules across biological membranes and, therefore, have been widely researched for use in theranostic applications. The attractive properties of the CNTs entice also their use in the brain environment. Cutting edge brain-specific therapies, capable of circumventing the physical and biochemical blockage of the blood-brain barrier, could be a precious tool to tackle brain disorders. With an increasing number of applications and expanding production, the effects of direct and indirect exposure to CNTs on cellular and molecular levels and more globally the general health, must be carefully assessed and limited. In this chapter, we review the most recent trends on the development and application of CNT-based nanotechnologies, with a particular focus on the carrier properties, cell internalisation and processing, and mechanisms involved in cell toxicity. Novel approaches for CNT-based systemic therapeutic brain delivery following intravenous administration are also reviewed. Moreover, we highlight fundamental questions that should be addressed in future research involving CNTs, aiming at achieving its safe introduction into the clinics.
Thiotepa‐based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia—A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Authors: Sandra Eder, Eric Beohou, Myriam Labopin, Jaime Sanz, Jürgen Finke, William Arcese, Reuven Or, Francesca Bonifazi, Mahmoud Aljurf, Gerard Socié, Jakob Passweg, Sebastian Giebel, Mohamad Mohty, Arnon Nagler
Journal: American Journal of Hematology (2016)

In this study, we analyzed a thiotepa‐based conditioning regimen for allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia, using the EBMT database. A total of 323 patients were identified. The median age was 43 years. Disease status at transplant was first complete remission (CR1) in 48.9%, CR2 in 21.7%, CR3 in 6.2%, while 23.2% of the patients had an active disease at the time of transplant. This was performed from a HLA‐matched sibling (49.8%) or a matched‐unrelated donor (51.2%). The incidence of acute graft‐vs.‐host disease (GvHD) (grade &gt; II) was 26.6%, while chronic GvHD occurred in 35.9% of the patients at 1 year (24.6% with extensive disease). With a median follow‐up of 16.8 months, the nonrelapse mortality was 12.4 and 25.3% at 100 days and 1 year, respectively. The relapse incidence at 1 year was 33.3% with no difference for patients in CR1 (27%). The one‐year leukemia‐free survival (LFS) and overall survival (OS) were 57 and 66%, respectively for the entire cohort and 50 and 66%, respectively in patients in CR1. Thiotepa/busulfan ± melphalan ( n = 213) in comparison to thiotepa/other ( n = 110) conditioning regimen resulted in higher relapse incidence at 1 year (34.9 vs. 30.3%, P = 0.016) and lower LFS (38.8 vs. 45.9%, P = 0.0203), while nonrelapse mortality (23.8 vs. 26.3%, n.s.) and OS (59.6 vs. 51.1%, P = 0.109) did not differ. This large study suggests that a thiotepa‐based conditioning for allogeneic transplantation in acute lymphoblastic leukemia is feasible and effective, with the main outcomes being comparable to those achieved with other regimens. Am. J. Hematol. 92:18–22, 2017. © 2016 Wiley Periodicals, Inc.
What to Do When the Managed Care Firm Says No
Authors: Susan M. Essock
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
P1042 : Deregulation of de novo lipogenesis can be associated with liver damage in patients with non alcoholic fatty liver disease
Authors: C. Rosso, C. Saponaro, L. Mezzabotta, E. Vanni, R. Gambino, F. Saba, R. Ibrahim Kamal Jouness, M. Gaggini, E. Buzzigoli, G.P. Caviglia, M.L. Abate, F. Salomone, A. Smedile, M. Rizzetto, M. Cassader, A. Gastaldelli, E. Bugianesi
Journal: Journal of Hepatology (2015)
A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer.
Authors: Charles N Catton, Himu Lukka, Jim A. Julian, Chu-Shu Gu, Jarad Martin, Stéphane Supiot, Peter W. M. Chung, Glenn Bauman, Jean-Paul Bahary, Shahida Ahmed, Patrick Cheung, Keen Hun Tai, Jackson Wu, Matthew Parliament, Mark Norman Levine
Journal: Journal of Clinical Oncology (2016)

5003 Background: Men with localized prostate cancer (PC) are often treated with high dose radiotherapy (RT) over 8-9 weeks. The α-β ratio which describes the dose-response of tumors and normal tissues to fractionated RT is low for PC. Hence, hypofractionation RT may be more efficacious in PC. Objective:To determine whether an 8-week course of escalated dose conformal RT can be compressed safely, and with similar efficacy into a 4-week course in intermediate risk PC. Methods: Men with intermediate risk PC (T1-2 Gleason 6 and PSA 10-20 ng/ml or T2b-c Gleason 6 and PSA < 20 ng/ml or T1-2 Gleason 7 and PSA < 20 ng/ml) were randomized to conventional (CON) RT, 78Gy in 39 fractions over 8 weeks or hypofractionated (HYP) RT, 60Gy in 20 fractions over 4 weeks, without hormone therapy. RT was planned to respect predefined dose constraints to a risk-adapted volume that included prostate +/- base of seminal vesicles. Daily image guidance was mandated and RT plans underwent real-time central review. The primary outcome is biochemical-clinical failure (BCF) defined by any of: PSA failure (nadir+2), hormonal intervention, clinical local or distant failure, or death. The trial was designed to show that the 5-year BCF of the HYP RT regimen is no higher than CON RT by up to 7.5% (hazard ratio [HR] up to 1.32) with 85% power and one-sided α = 5%. Acute and late GU/GI toxicity were assessed using RTOG criteria. Results:Between 2006 and 2011, 1,206 men from 27 sites in Canada, Australia and France were allocated to HYP RT (608) or CON RT (598). Mean age was 71 (48-88) years. Baseline characteristics were similar between arms. Median follow-up is 6.0 years. To date, 164 patients receiving HYP RT experienced a BCF event compared to 173 in the CON RT group. The BCF event rate at 5 years in both arms was 21%. The observed HR is 0.96 with 90% CI, 0.80 to 1.15. Overall 75 patients have died in each group. GU/GI toxicity grade > 3 was comparable in the acute period; however, late toxicity favored the HYPO RT arm: 3.5% vs. 5.4%, diff = -1.9%, 95% CI, - 4.3 to 0.43%. Conclusion: The HYP RT regimenwas not inferior to conventional RT with no increase in acute or late toxicity. Thus, it is a consideration for men with intermediate risk PC. Clinical trial information: NCT00304759.
Fludarabine, Bendamustine, and Rituximab (FBR) Chemoimmunotherapy Is a Safe and Active Regimen for Relapsed/Refractory CLL with in Vivo Mechanism of Action for Combination Chemotherapy
Authors: William G. Wierda, Kumudha Balakrishnan, Alessandra Ferrajoli, Susan O'Brien, Jan A. Burger, Tapan M. Kadia, Jorge E. Cortes, Francesco Paolo Tambaro, Annette Jalayer, Susan Lerner, Michael J. Keating, Varsha V. Gandhi
Journal: Blood (2012)
Phase II Study of Bortezomib in Waldenstrom’s Macroglobulinemia: Results of WMCTG Trial 03-248.
Authors: Steven Treon, Zachary R. Hunter, Jeffrey Matous, A. Badros, Robin M. Joyce, Brian Mannion, Ranjana Advani, D. Cook, J. Songer, John Hill, Bruce R. Kaden, D. Sharon, R. Steiss, Andrew R. Branagan, Christopher J. Patterson
Journal: Blood (2005)
Increased Expression of the cGMP-Specific Phophodiesterase, PDE9A, in Sickle Cell Disease (SCD) Reticulocytes and Neutrophils, and Induction of Erythroid γ Globin Expression and Reduction of SCD Neutrophil Adhesion Following PDE9A Inhibition.
Authors: Camila B. Almeida, Sara T.O. Saad, Fernando F. Costa, Nicola Conran
Journal: Blood (2007)
Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia.
Authors: Jeffrey W. Tyner, Christopher A. Eide, Eric P. Stoffregen, Marc Loriaux, Stephanie G. Willis, Norbert Gattermann, Tibor Kovacsovics, Brian J. Druker, Michael W. Deininger
Journal: Blood (2006)
Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023
Authors: Jesus San Miguel, Maria-Victoria Mateos, Jatin J. Shah, Enrique M. Ocio, Paula Rodriguez-Otero, Donna Reece, Nikhil C. Munshi, David Avigan, Yang Ge, Arun Balakumaran, Patricia Marinello, Robert Z. Orlowski, David Siegel
Journal: Blood (2015)
Breast cancer survivorship (CS): A comparison of perceptions in the acute and extended survival phases
Authors: D. M. Pandya, L. Peterson, B. H. Pollock, A. Karnad
Journal: Journal of Clinical Oncology (2008)

20599 Background: There are three phases of CS: acute, extended, and permanent. While fear of recurrence, anxiety, and physical limitations are constant elements of the extended survival phase (ESP), other patient perceptions during this phase are not well known. This study examined perceptions among patients in the ESP and compared them to the acute survival phase (ASP), which was studied previously in the pilot project. Methods: Forty-eight female breast cancer patients who have completed chemotherapy and are in remission were individually interviewed. Subjects were queried about multiple areas of survivorship including their social support system, satisfaction and adherence with treatment, satisfaction and trust of their primary care physician (PCP), nursing staff, and medical oncologist, distress level (0- 10), and quality of life. Results: Overall, 96% of patients in the ESP were satisfied with their treatment and 88% felt they were well-informed about their cancer and treatment as compared to 63% and 53% in the ASP, respectively. In the ESP, 98% of patients were satisfied with the medical care they received with regards to their physical well-being, 85% for psychological well-being, 77% for social well- being, and 67% for spiritual well-being as compared to 67%, 57%, 43%, and 23% in the ASP, respectively. In the ESP, 79% reported satisfaction with their PCP, 98% with nursing staff, and 98% with their medical oncologist, as compared to 60%, 83%, and 63% in the ASP, respectively. Patients in the ESP had lower average distress scores, 4.5 versus 5.2 in the ASP. 46% of patients in the ESP were treated for depression compared with 27% in the ASP. 58% of patients in the ESP listed 7+ members in their social support group compared to 28% in the ASP. Conclusions: This pilot study of perceptions and beliefs of adult cancer survivors in the ESP identified that though patients are satisfied in more areas than in the ASP, there is still a need to better address social and spiritual well-being and identify depression, while continuing to provide ideal medical care. In the future, more studies should be done in adult patients in all phases of CS. No significant financial relationships to disclose.
Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results
Authors: Ravi Vij, Carol Ann Huff, William I. Bensinger, David S. Siegel, Sundar Jagannath, Jesus Berdeja, Nikoletta Lendvai, Daniel Lebovic, Larry D. Anderson, Caitlin L. Costello, Keith E. Stockerl-Goldstein, Jacob P. Laubach, Laurence Elias, Fong Clow, Maria Fardis, Thorsten Graef, Elizabeth Bilotti, Paul G. Richardson
Journal: Blood (2014)
A Potent <i>In Vivo</i> Antitumor Efficacy of Novel Recombinant Type I Interferon
Authors: Kang-Jian Zhang, Xiao-Fei Yin, Yuan-Qin Yang, Hui-Ling Li, Yan-Ni Xu, Lie-Yang Chen, Xi-Jun Liu, Su-Jing Yuan, Xian-Long Fang, Jing Xiao, Shuai Wu, Hai-Neng Xu, Liang Chu, Kanstantsin V. Katlinski, Yuliya V. Katlinskaya, Rong-Bing Guo, Guang-Wen Wei, Da-Cheng Wang, Xin-Yuan Liu, Serge Y. Fuchs
Journal: Clinical Cancer Research (2016)

Antiproliferative, antiviral, and immunomodulatory activities of endogenous type I IFNs (IFN1) prompt the design of recombinant IFN1 for therapeutic purposes. However, most of the designed IFNs exhibited suboptimal therapeutic efficacies against solid tumors. Here, we report evaluation of the
Racial differences in the perception of lung cancer: Data from the 2005 Health Information National Trends Survey (HINTS)
Authors: C. S. Lathan, C. Okechukwu, B. F. Drake, G. Bennett
Journal: Journal of Clinical Oncology (2007)

6556 Background: Black men have the highest rates of lung cancer incidence and mortality in the US, and yet continue to obtain treatment at lower rates than White patients. Racial differences in the perception of lung cancer in the population could contribute to racial disparities in seeking timely treatment. Methods: Data are from the 2005 HINTS survey. Sample design was random digit dialing of listed telephone exchanges in US. Complete interviews were conducted on 5491 adults, of which 1872 respondents were assigned to receive questions pertaining to lung cancer. All analyses were conducted on this subset of respondents. SAS callable SUDAAN was used to calculate χ 2 tests and perform logistic regression analyses to model racial differences in perceptions of lung cancer. All estimates were weighted to be nationally representative of US population; jack knife weighting method was used for parameter estimation. Results: Black and White patients shared many of the same beliefs about lung cancer mortality, and etiology. African Americans were more likely than Whites to agree that its hard to follow recommendations about preventing lung cancer (OR 2.05 1.19–3.53 95% CI), to avoid evaluation for lung cancer due to fear of having the disease (OR 3.32 1.84–5.98 95% CI), and to believe that patients with lung cancer would have pain or other symptoms before diagnosis (OR 2.20 1.27–3.79 95% CI). Conclusions: African Americans are more likely to hold beliefs about lung cancer that could interfere with prevention and treatment of lung cancer. No significant financial relationships to disclose. [Table: see text]
Screening for brain metastasis (bm) in patients (pts) with stage III non-small cell lung cancer (nsclc): has magnetic resonance imaging (mri) an additive value compared to computed tomography (ct)?
Authors: Lydia Hendriks, A Dingemans, G Bootsma, N Scheppers, P Hofman, B Brans, Dirk De Ruysscher
Journal: Journal of Thoracic Oncology (2012)
Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma.
Authors: Michael Wang, Robert Knight, Melitios Dimopoulos, David Siegel, S. Vincent Rajkumar, Thierry Facon, Raymond Alexanian, Zhinuan Yu, Jerome Zeldis, Marta Olesnyckyj, Donna Weber
Journal: Blood (2006)